Cholesterol Reducer

esperion

Esperion Starts Phase 2 Trial Of Cholesterol Buster

The Plymouth pharmaceutical developer Esperion Therapeutics Thursday announced that it has initiated a Phase 2 clinical study for ETC-1002, the company’s lead product candidate.  ETC-1002 is a novel small molecule compound that has demonstrated preclinical […]

01/06/2011

Follow

Get every new post delivered to your Inbox.

Join 1,993 other followers